Nature - USA (2020-09-24)

Article

a

0123465

PK Lo

(n=2)

PK Hi

(n=2)

PK Hi + AZTH

(n=2)

02448729 6 120 144 024487296120144

0.001

0.01

0.1

1

10

0.001

0.01

0.1

1

10

0.001

0.01

0.1

1

10

0.001

0.01

0.1

1

10

024487296120144

0.001

0.01

0.1

1

10

024487296120144

0.001

0.01

0.1

1

10

02448729 6 120 144

02448729 6 120 144

Time since treatment initiation (hours)

Plasma Total blood

HCQ plasma conc. (μg/mL)

b

c

0.0

1.5

3.0

4.5

6.0

7.5

9.0

HCQ blood conc. (μg/mL

)

R=0.84, p < 0.001

0.0 0.5 1.0 1.5 2.0 2.5 3.0

HCQ plasma conc. (μg/mL)

Extended Data Fig. 4 | Plasma and blood HCQ concentrations of six
uninfected NHPs. a, Pharmacokinetic (PK) study design. Three groups of two
cynomolgus macaques received either a high (Hi) dose regimen of HCQ
composed of a loading dose of 90 mg kg−1 and a daily maintenance dose of
45 mg kg−1 or a low (Lo) dose regimen composed of a 30 mg kg−1 loading dose

and a daily maintenance dose of 15 mg kg−1. One group received AZTH in

combination with HCQ with a loading dose of 36 mg kg−1 followed by an

18 mg kg−1 daily maintenance dose. b, Individual plasma and blood HCQ

concentrations (conc.) up to 5–6 days after the initiation of treatment.

c, Correlation between plasma and blood HCQ concentrations.